chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Dr. chenguang zhang at The Tumor Hospital of Xinjiang Medical University, China.

Dr. Chenguang Zhang 🧑‍⚕️ is a distinguished breast cancer surgeon and researcher, renowned for his expertise in diagnosing and treating both benign and malignant breast tumors. 🩺 He excels in surgeries including mastectomy, breast-conserving techniques, and reconstruction. 🧬 His cutting-edge research focuses on endocrine therapy resistance and molecular mechanisms in breast cancer, leading multiple high-level funded projects. 🔬 He holds a patent for surgical forceps 🛠️ and has authored numerous publications in SCI-indexed journals 📚. As a committed academic and member of several prestigious medical associations 🤝, Dr. Zhang is driving innovation in cancer diagnosis, treatment, and personalized care.

Publication Profile 

Orcid

Education

Dr. Chenguang Zhang 🧑‍⚕️ is highly proficient in the differential diagnosis of benign and malignant breast tumors 🔬. He is skilled in advanced breast cancer surgical techniques, including modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and both implant-based and autologous tissue breast reconstruction 🏥. His research primarily targets the mechanisms behind endocrine therapy resistance in breast cancer 🎯. A leader in scientific innovation, he has directed multiple high-impact research projects at provincial and ministerial levels 🧪📊. Dr. Zhang’s commitment to precision medicine and surgical excellence is shaping the future of breast oncology care.

Professional Memberships

Dr. Chenguang Zhang 🧑‍⚕️ is an active contributor to the advancement of breast oncology through multiple prestigious professional memberships 🤝. He is a member of the Young Scholars Group of Breast Oncology under the Oncology Branch of the Chinese Medical Association 🧬, and serves on the Professional Committee of Oncoplastic Surgery within the China Anti-Cancer Association 🎗️. He is part of the Youth Expert Group 🌟 and the Young Scholars Group of the Science Popularization Branch of the Chinese Medical Doctor Association 📚. Additionally, he contributes to the Breast Minimally Invasive Plastic Surgery and Reconstruction Group within the Rehabilitation Society of the China Anti-Cancer Association.

Research Focus 

Dr. Chenguang Zhang’s research 🧪 focuses on breast cancer biology 🩺, particularly triple-negative breast cancer (TNBC) and endocrine therapy resistance in ER-positive tumors. His studies explore molecular pathways such as PI3K/AKT/mTOR, Wnt signaling, ferroptosis regulation, and autophagy inhibition 🧬. He investigates prognostic biomarkers, drug resistance mechanisms 💊, and advanced surgical strategies including sentinel lymph node biopsy and reconstructive techniques 🔬. His work contributes significantly to precision oncology, translational medicine, and clinical innovation in breast tumor management 🎗️. With a strong emphasis on molecular diagnostics, therapeutic resistance, and immunological responses, his research advances breast cancer treatment outcomes globally.

Publication Top Notes

  • Typical presentation of neurofibromatosis type I in a patient with giant cutaneous neoplasm and café au lait spots: A case report.
  • FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy.
  • Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
  • A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
  • MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.
  • HOXD Antisense Growth-Associated Long Noncoding RNA Promotes Triple-Negative Breast Cancer Progression by Activating Wnt Signaling Pathway.
  • Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer.
  • Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.
  • Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.

ETTIE Rosenberg | Pharmaceutical Law and Ethics | Best Researcher Award

Published on by Top Pharmaceutical

ETTIE Rosenberg | Pharmaceutical Law and Ethics | Best Researcher Award

Dr. ETTIE Rosenberg at West Coast University School of Pharmacy, United States.

Dr. Ettie Rosenberg, PharmD, JD 🎓⚖️ is a distinguished professor, pharmacist, and attorney with an impressive dual doctorate in Pharmacy and Law from USC and Southwestern Law School. With decades of experience, she blends expertise in pharmacy education, healthcare law, and ethics. 💊📚 She has held various leadership and teaching roles at West Coast University and contributed to community health through projects like Vote and Vax® 💉🗳️. A Supreme Court Bar member and expert forensic consultant, Dr. Rosenberg continues to inspire through innovation in teaching and interprofessional scholarship. 🌟👩‍🏫 Her work empowers future healthcare leaders and strengthens ethical practice in pharmacy.

Publication Profile 

Scopus

Education

Dr. Ettie Rosenberg 🎓 holds an exceptional academic background that spans both law and pharmacy. She earned her Juris Doctorate (JD) in 1999 from Southwestern University School of Law ⚖️ in Los Angeles, California, specializing in health law. Prior to that, she completed her Doctor of Pharmacy (PharmD) 💊 from the University of Southern California (USC). Her academic journey began with pre-pharmacy studies 🧪 at the University of California, Los Angeles (UCLA). Additionally, she is multilingual, fluent in Spanish, French, and Hebrew 🌍🗣️. This unique blend of legal and pharmaceutical expertise empowers her to lead across healthcare and education sectors.

Experience

Dr. Ettie Rosenberg, PharmD, JD 🎓 is a distinguished educator with a rich portfolio of academic contributions in pharmacy law, ethics, healthcare systems, and public health. She has consistently led and developed key courses such as PHAR 838 Pharmacy Law & Ethics ⚖️, PHAR 619 U.S. Healthcare Systems 🏥, and PHAR 623 Advocacy & Debate: Mock Trial 🎤. Her dynamic instruction spans across interprofessional ethics, substance abuse, evidence-based practice, and capstone courses. Through innovative teaching methods and real-world applications 💡📘, she empowers pharmacy students to navigate complex legal, ethical, and clinical challenges with competence and integrity.

Awards

Dr. Ettie Rosenberg, PharmD, JD 🌟 has earned numerous accolades throughout her illustrious career. She received the 2017 AACP Innovations in Teaching Honorable Mention 🏆 for her impactful mock trial teaching method and was honored as Professor of the Year (2016) 👩‍🏫 by West Coast University. Earlier recognitions include the 1998 Health Care Law Scholarship 💼, Harvard Bluebook Award for Editing 📘, and the 1991 Alumna of the Year Award 🎓. A member of the Rho Chi Pharmacy Honor Society since 1978 🧪, she also completed a pediatric oncology fellowship at USC that same year 🧒💊, showcasing her dedication to excellence in education and healthcare.

Research Focus 

Dr. Ettie Rosenberg’s research focus lies at the dynamic intersection of pharmacy law, ethics, and education ⚖️📚💊. As a legal and pharmacy scholar, she explores how legal frameworks impact pharmaceutical practices, patient rights, public health, and healthcare policy 🏥📜. Her academic endeavors emphasize mock trial simulations, inter-professional education, and evidence-based legal instruction within pharmacy curricula 🎓⚖️🔬. Dr. Rosenberg also investigates regulatory challenges, professional accountability, and law’s role in optimizing patient outcomes 🤝👩‍⚕️. Her interdisciplinary work fosters ethical decision-making and critical thinking among future pharmacists, bridging gaps between law, education, and clinical practice.

Publication Top Notes

  • UPJE: Most pharmacy law educators have heard of it, but support remains divided

Souhire Belloumi | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Souhire Belloumi | Formulation Science | Best Researcher Award

Ms. Souhire Belloumi at Faculty of Sciences of Tunis and Center of Biotechnology of Borj Cedria, Tunisia.

Ms. Souhire Belloumi is a dynamic young researcher pursuing her Ph.D. in Biological Sciences at the University of Tunis El-Manar, Tunisia 🇹🇳. With dual Master’s degrees in Biological Sciences and Environmental Biomonitoring, and a Bachelor’s in Medical Biotechnology 🧫, she specializes in bioactive compounds, molecular diagnostics, and food preservation 🌿🍗. Her research spans from natural preservatives to vaccine development, combining LC-MS/MS, PCR, and biochemistry tools 🔍🧪. She has collaborated internationally, including a stint at the University of Pisa 🇮🇹, and authored multiple impactful publications 📚. Her passion lies in innovating sustainable solutions for health and food security.

Publication Profile 

Scopus

Education

Ms. Souhire Belloumi has cultivated a strong academic foundation in life sciences. She is currently pursuing her Ph.D. in Biological Sciences (2019–2024) at the University of Tunis El-Manar 🧬. Prior to this, she earned a Master’s in Biological Sciences (2018–2019) and another in Environmental Biomonitoring (2016–2018) from the University of Carthage 🌿🧪. Her academic journey began with a Bachelor’s degree in Medical Biotechnology with a focus on Molecular Engineering (2013–2016) at the High Institute of Medical Technologies, Tunis 🧫. Her multidisciplinary education equips her with robust expertise in molecular biology, environmental science, and biotechnology.

Experience

Ms. Souhire Belloumi has rich research experience across molecular biology, virology, and natural product chemistry. At the University of Pisa, Italy 🇮🇹 (Oct–Dec 2023), she characterized bioactive plant compounds using LC-MS/MS. As a Research Scientist at the Center of Biotechnology of Borj-Cedria (2020–2023), she explored natural biopreservatives 🧪 for poultry, partnering with Poulina Holdings 🐔. Earlier roles include research on essential oils, virus diagnostics 🌿🦠, and vaccine development at Tunisia’s Pasteur Institute 💉. Her hands-on work in molecular diagnostics, compound isolation, and industrial applications highlights her commitment to bridging lab research and real-world impact.

Research Focus 

Ms. Souhire Belloumi focuses her research on natural bioactive compounds with applications in food preservation, microbiology, and environmental health 🌿🍗🦠. Her work emphasizes the synergistic use of essential oils to extend the shelf life of poultry products, showcasing innovations in natural biopreservatives 🍃🧪. She skillfully integrates chemical analysis, molecular biology, and biochemistry to evaluate antimicrobial, antioxidant, and insecticidal properties of plant-derived substances 🔍💧🧬. Her interdisciplinary approach not only advances food safety and sustainability 🌍 but also contributes to the development of eco-friendly alternatives to synthetic preservatives 🚫🧫✅, making her a valuable asset in biotechnology and food science.

Publication Top Notes

  • Combined essential oils as natural chicken meat preservatives: chemical composition, biological activities, synergy and shelf-life extension potential

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile 

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus 

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

  • Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction
  • A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*
  • A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction
  • Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*
  • Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*
  • A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**
  • Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.
  • A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold
  • Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization
  • Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications
  • A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous
  • Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine
  • Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials
  • Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Mrs. Fenghua Wu at Hubei university of chinese medcine, China.

Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🎓. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology 🔬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals 📚. Honored as a “Teaching Expert” and COVID-19 frontline contributor 🏅, she also serves as a Guest Editor for Frontiers in Immunology.

Publication Profile 

Scopus

Education

Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🏥. She currently teaches physiology and is actively engaged in oncology research 🔬 at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China 🇨🇳. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.

Professional Memberships

Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China 🇨🇳. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange 🔬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.

Research Focus 

Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) 🎯. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.

Publication Top Notes

  • Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
  • Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway

Angela Sardaro | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Angela Sardaro | Immunotherapy | Excellence in Research

Assoc. Prof. Dr. Angela Sardaro at ASL Lecce, Italy.

Assoc. Prof. Dr. Angela Sardaro is a distinguished Italian academic and medical professional specializing in Radiotherapy and Diagnostic Imaging. She has served as a professor at the University of Bari Aldo Moro, coordinating degree programs and teaching across multiple disciplines, including Radiology, Oncology, and Medical Imaging. With over 15 years of academic experience, she has guided numerous theses and led scientific seminars. Dr. Sardaro’s prolific research output includes 81 indexed publications, an h-index of 15, and 842 citations 📈. Her contributions extend globally, with collaborations in the UK and Italy, reinforcing her impact in oncology and radiological science.

Publication Profile 

scopus

Education

Assoc. Prof. Dr. Angela Sardaro has demonstrated outstanding commitment to medical education 👩‍⚕️📚, coordinating the Degree Course in Radiologic Imaging and Radiotherapy Techniques at the University of Bari Aldo Moro 🎓. With over 15 years of teaching experience across various undergraduate and postgraduate programs, she has taught core disciplines like Radiotherapy, Radiobiology, and Diagnostic Imaging 🧬🔬. Her academic service spans doctoral programs, master’s training in pain therapy, and prestigious collaborations with institutions in Florence and the UK 🇮🇹🇬🇧. Dr. Sardaro has delivered 1,440 hours of lectures and 4,160 hours of professional training 📊, shaping future generations in radiological sciences.

Experience

Assoc. Prof. Dr. Angela Sardaro has made a remarkable impact on clinical education and hands-on training in radiological sciences 👩‍⚕️🧲. She has guided radiologic technologists, medical students, and postgraduates through innovative programs that incorporate cutting-edge technologies like PET/CT, proton therapy, and radiogenomics 💡🧬. Her dedication to advancing clinical competence is evident in the numerous experimental and clinical theses completed under her mentorship 📖🎓. By blending theory with real-world application, she has nurtured a generation of professionals equipped to meet the evolving challenges of diagnostic imaging and radiation therapy.

Research Focus 

Assoc. Prof. Dr. Angela Sardaro’s research focus lies at the intersection of oncologic radiotherapy, advanced diagnostic imaging, and radiation-induced toxicities 🎯🧲. Her work spans critical areas such as hypofractionated radiotherapy, prostate cancer, head and neck squamous cell carcinoma, breast cancer survivorship, and radiogenomics 📊🧬. She also investigates rare radiation-associated tumors like angiosarcomas, while leveraging cutting-edge tools like 18F-FCH PET/CT, MR imaging, and stereotactic radiosurgery 🧠🔬. Her systematic reviews and meta-analyses contribute to refining treatment protocols and improving patient outcomes 🩻👩‍⚕️. Dr. Sardaro’s impactful research bridges clinical innovation with evidence-based radiation oncology.

Publication Top Notes

  • Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
  • Nodal assessment and extranodal extension in head and neck squamous cell cancer: insights from computed tomography and magnetic resonance imaging
  • Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments
  • Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity
  • Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease
  • Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis
  • Role of 18F-FCH PET/CT in Detecting Recurrences of Prostate Cancer After Curative Treatments

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome